WHO advises against two drugs for treatment of non-severe Covid-19

The WHO Guideline Development Group (GDG) has put out new guidance advising against the use of fluvoxamine and colchicine for patients with mild or moderate Covid-19. Fluvoxamine (an antidepressant) and colchicine (a gout drug) are commonly used, inexpensive drugs that have received considerable interest as potential Covid-19 treatments during the pandemic. However, there has been ongoing uncertainty about the overall benefits and safety profile of these drugs. Insufficient evidence that the drugs improve important outcomes, and both carry potential harms In making their decision, the GDG looked at data from three randomised controlled trials (RCTs) involving over 2,000 patients on